Key result
Therapeutic hypothermia protected against heat stroke-induced arterial hypotension (71 mmHg vs 30 mmHg) and promoted left ventricular performance, resulting in 100% survival compared to 0% in untreated rats.
Why the study?
It was unknown whether therapeutic hypothermia acts as cardioprotective management for heat stroke.
Does therapeutic hypothermia improve arterial hypotension and left ventricular performance in a rat model of heat stroke?
Does therapeutic hypothermia improve arterial hypotension and left ventricular performance in a rat model of heat stroke?
Therapeutic hypothermia protects against heat stroke-induced arterial hypotension by promoting left ventricular performance and reducing myocardial injury in a rat model.
Answers are grounded in this paper and cite their sources.
Therapeutic hypothermia merits human trials in heat stroke; leaves open translation from rat models to clinical practice.
We aimed to ascertain whether therapeutic hypothermia (TH) acts as cardioprotective management for heat stroke (HS). Adult male rats under general anesthesia were exposed to whole-body heating (43°C for 70 min) to induce HS. Rats with HS displayed hyperthermia (core body temperature 42°C vs. 36°C); hypotension (30 mmHg vs. 90 mmHg mean arterial blood pressure); suppressed left ventricular (LV) performance (stroke volume 52 μl/min vs. 125 μl/min), ejection fraction (0.29% vs. 0.69%), relaxation factor (72 ms vs. 12 ms), and arterial elastance (0.31 mmHg/ μl vs. 10 mmHg/ μl); increased myocardial injury markers (e.g., creatine kinase-MB: 86 U/L vs. 24 U/L, cardiac troponin I: 3.08 ng/ml vs. 0.57 ng/ml); increased myocardial oxidative stress markers (e.g., malondialdehyde: 6.52 nmol/mg vs. 1.06 nmol/mg, thiobarbituric acid-reactive substances: 29 nmol/g vs. 2 nmol/g); decreased myocardial antioxidants (e.g., superoxide dismutase: 6 unit/mg vs. 17 unit/mg, reduced glutathione: 0.64 nmol/mg vs. 2.53 nmol/mg); increased myocardial proinflammatory cytokines (e.g., tumor necrosis factor-α 3200 pg/ml vs. 1000 pg/ml, interleukin-6: 668 pg/ml vs. 102 pg/ml); and increased cardiac damage scores (2.2 vs. 0.3). TH therapy significantly reversed the following conditions: HS-induced hyperthermia (37.5°C core body temperature), hypotension (71 mmHg), suppressed LV performance (stroke volume: 97 μl/min, ejection fraction: 0.65%, relaxation factor: 39 ms, and arterial elastance: 0.99 mmHg/μl), increased myocardial injury markers (e.g., creatine kinase-MB: 37 U/L, cardiac troponin I: 1.06 ng/ml), increased myocardial oxidative stress markers (e.g., malondialdehyde: 2.68 nmol/mg, thiobarbituric acid-reactive substances: 12.3 nmol/g), decreased myocardial antioxidants (e.g., superoxide dismutase: 13.3 unit/mg, reduced glutathione: 2.71 mmol/mg), increased myocardial proinflammatory cytokines (e.g., tumor necrosis factor-α 1500 pg/ml, interleukin-6: 108 ng/ml); and increased cardiac damage scores (0.9). We thus conclude that TH protects against HS-induced arterial hypotension by promoting LV performance in rats. These results add to the literature regarding the use of TH as cardioprotective management for HS.
No takes yet. Share an insight, caveat, or question.
Ko et al. (2020) studied Heat stroke (n=60). Therapeutic hypothermia vs. Non-therapeutic hypothermia (26°C for 30 min) was evaluated on Mean arterial blood pressure (p=<0.01). Therapeutic hypothermia protected against heat stroke-induced arterial hypotension (71 mmHg vs 30 mmHg) and promoted left ventricular performance, resulting in 100% survival compared to 0% in untreated rats.
Synapse has enriched 10 related papers. Consider them for comparative context: